Abstract Number: 1504 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thromboembolism Among Patients with VTE Association with Rheumatoid Arthritis
Increased risk of thromboembolism among patients with VTE association with Rheumatoid Arthritis Background/Purpose: Rheumatoid arthritis (RA), is among most common autoimmune conditions manifested by progressive and…Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival
Background/Purpose: While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …Abstract Number: 2964 • 2015 ACR/ARHP Annual Meeting
Influences of Various Factors on Survival of Patients Treated with Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Patients with Connective Tissue Diseases
Background/Purpose: In patients with connective tissue disease (CTD), especially systemic sclerosis (SSc), several mechanisms have been implicated for the development of pulmonary hypertension (PH), including…Abstract Number: 2985 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database
Background/Purpose : SSc related PH carries a high mortality; with SSc-PH related to restrictive lung disease (RLD) having worse prognosis and more rapid time to…Abstract Number: 516 • 2014 ACR/ARHP Annual Meeting
The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study
Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often…Abstract Number: 2697 • 2014 ACR/ARHP Annual Meeting
Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension
Background/Purpose: Lung transplantation is often the most viable option for patients with severe systemic sclerosis (SSc)-associated interstitial lung disease (ILD) that is unresponsive to pharmacologic…Abstract Number: 1691 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients with Pulmonary Hypertension Have a Lower Change in End Tidal Carbon Dioxide Following Three Minutes of Step Exercise Than Systemic Sclerosis Patients without Pulmonary Hypertension: A Cross-Sectional Study
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients with systemic sclerosis (SSc). Transthoracic echocardiogram and pulmonary function testing are standard noninvasive…Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting
Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). Although medications have improved their prognosis, optimal therapy remains undefined.…Abstract Number: 734 • 2014 ACR/ARHP Annual Meeting
Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Background/Purpose Lower socioeconomic status (SES) and male gender have been associated with worse survival in idiopathic pulmonary arterial hypertension (PAH). Pulmonary Hypertension Assessment and Recognition…Abstract Number: 2588 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of morbidity and mortality in patients with connective tissue diseases (CTD). Patients with anti-U1-RNP antibodies belong to…Abstract Number: 2591 • 2013 ACR/ARHP Annual Meeting
Scleroderma Renal Crisis and Pulmonary Arterial Hypertension Are Very Rare In The Same Patient
Background/Purpose: Systemic Sclerosis (SSc) is associated with occlusive vasculopathy resulting in digital ischaemia, telangiectasia, scleroderma renal crisis (SRC) and pulmonary arterial hypertension (PAH). SRC and…Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting
Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Background/Purpose: Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…Abstract Number: 2568 • 2012 ACR/ARHP Annual Meeting
The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Giant Cell Arteritis: A Population-Based Cohort Study
Background/Purpose: A recent hospital-based study has suggested an 8 fold increased risk of pulmonary embolism (PE) in individuals with polymyalgia rheumatica in the year following…Abstract Number: 1712 • 2012 ACR/ARHP Annual Meeting
The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis
Background/Purpose: Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg on right heart catheterization (RHC), is a leading cause of…
ACR Meeting Abstracts